WHO/EMA Monograph Plants · European
Matricaria chamomilla
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Matricaria chamomilla is a flowering herb whose primary bioactive compounds, the flavonoid apigenin and the terpenoid alpha-bisabolol, drive its therapeutic effects. Apigenin binds GABA-A receptors to produce mild anxiolytic and antispasmodic actions, while alpha-bisabolol inhibits pro-inflammatory enzymes including COX-1 and COX-2.
Matricaria chamomilla (German chamomile) is an annual herb from the Asteraceae family, native to Europe and widely cultivated globally. The medicinal parts are the dried flower heads (flos) or steam-distilled essential oil (aetheroleum), with the oil rich in sesquiterpenes and flavonoids. Commercial extracts are often standardized to 1.2-2.5% essential oil or 0.24-0.32% apigenin-7-glucoside.
The EMA/HMPC monographs classify chamomile under 'traditional use' rather than 'well-established use' due to insufficient clinical trial evidence. Several clinical studies were reviewed but deemed inadequate due to lack of comparators or robust design. No specific RCTs, meta-analyses, or PubMed PMIDs are available in the research dossier.
For dried flowers (flos): 1-3 g/day as herbal tea infusion for gastrointestinal use, or 3-5 g/day for topical semi-solid forms. For essential oil (aetheroleum): 1-3 mg/day oral or 0.02-5% diluted for topical/bath use. Consult a healthcare provider before starting any new supplement.
Matricaria chamomilla (German chamomile) is consumed primarily as a herbal infusion rather than a food source, so conventional macronutrient profiling is of limited relevance; however, key constituents and bioactive compound concentrations are well-characterised. Dried chamomile flower heads contain approximately 0.24–1.9% essential oil by dry weight, dominated by (-)-α-bisabolol (up to 50% of essential oil fraction) and its oxides (bisabolol oxide A and B), which are primary anti-inflammatory and antispasmodic contributors. Chamazulene, formed from matricine during steam distillation, constitutes 1–15% of the essential oil and is responsible for the characteristic blue colour; it exhibits notable anti-inflammatory activity via COX inhibition pathways. Flavonoid content ranges from 1–3% dry weight, with apigenin (apigenin-7-glucoside being the predominant glycoside at approximately 0.5–1.0 mg/g dry weight) identified as the principal bioactive flavonoid; apigenin demonstrates affinity for GABA-A receptors contributing to mild anxiolytic effects observed in animal models. Luteolin and quercetin glycosides are present in smaller quantities (~0.1–0.3 mg/g dry weight). Phenolic acids include caffeic acid, chlorogenic acid, and ferulic acid at trace levels (0.05–0.2 mg/g dry weight). Coumarins (herniarin and umbelliferone) are present at approximately 0.1% dry weight. A standard chamomile tea infusion (1 g dried flowers per 150 mL water, 5-minute steep) yields approximately 0.5–2 mg apigenin-7-glucoside, with significantly lower extraction of essential oil volatiles and lipophilic bisabolol compounds, limiting their bioavailability via this route. Polysaccharides (mucilaginous compounds) are present at 3–10% dry weight and may contribute to demulcent effects on mucous membranes. Crude protein content of dried flowers is approximately 10–12% dry weight, though this is not nutritionally relevant in typical consumption amounts. Minerals present in dried flowers include potassium (~10–15 mg/g), calcium (~5–8 mg/g), and magnesium (~2–3 mg/g) at trace nutritional levels. Bioavailability note: apigenin from chamomile tea is bioavailable in humans with detectable plasma concentrations post-ingestion (Cmax approximately 0.1–0.3 µmol/L reported in limited pharmacokinetic studies); bisabolol bioavailability via oral infusion is poor due to hydrophobic nature. Topical formulations standardised to 0.5–2% α-bisabolol or 1–2% chamomile extract demonstrate superior delivery of lipophilic actives to skin tissue.
Apigenin, a flavone concentrated in chamomile flower heads, acts as a partial agonist at benzodiazepine-binding sites on GABA-A receptors, producing anxiolytic and smooth-muscle relaxant effects without significant sedation at typical doses. Alpha-bisabolol and chamazulene inhibit arachidonic acid metabolism by suppressing COX and 5-LOX enzyme activity, reducing prostaglandin and leukotriene synthesis to attenuate local inflammation. Chamazulene, formed from matricine during steam distillation of the essential oil, also scavenges reactive oxygen species, contributing to the herb's antioxidant and tissue-soothing properties.
A 2009 randomized controlled trial (n=57, Amsterdam) found standardized chamomile extract (220–1100 mg/day apigenin-enriched) significantly reduced HAM-A anxiety scores versus placebo over 8 weeks, representing modest but statistically significant anxiolytic benefit. For gastrointestinal complaints, evidence remains largely based on traditional use and in vitro smooth-muscle studies; no large-scale RCTs have confirmed efficacy for irritable bowel syndrome specifically. The European Medicines Agency (EMA) classifies chamomile for oral and topical use under 'traditional use' rather than 'well-established use,' reflecting a lack of adequate clinical trial data meeting modern standards. Topical chamomile preparations showed mild benefit for atopic eczema in small comparative studies against hydrocortisone cream, but effect sizes were modest and sample sizes (n<160) limit generalizability.
Chamomile is generally well tolerated at recommended doses (300–1500 mg dried flower extract daily), with the most common adverse effects being allergic reactions, particularly in individuals sensitive to Asteraceae/Compositae family plants such as ragweed, chrysanthemums, or marigolds. Rare cases of anaphylaxis have been documented, so individuals with known pollen allergies should use chamomile with caution. Chamomile may potentiate the effects of warfarin and other anticoagulants, as coumarin derivatives present in the plant inhibit platelet aggregation; concurrent use should be monitored by a healthcare provider. Chamomile is not recommended during pregnancy due to potential uterotonic effects observed in animal models, and its safety during lactation has not been adequately established in human studies.
